 |
|
A Multiple-Dose, Controlled Study of Phenelzine in Depression-Anxiety States
C. Lewis Ravaris, PhD, MD;
Alexander Nies, MD;
Donald S. Robinson, MD;
John O. Ives, MD;
Kathleen R. Lamborn, PhD;
Lorraine Korson, MS
Arch Gen Psychiatry. 1976;33(3):347-350.
Abstract
• In a double-blind, controlled experiment, 62 outpatients with symptoms of depression with anxiety were selected for treatment with phenelzine sulfate, 60 mg daily, phenelzine sulfate, 30 mg daily, or placebo for six weeks. Forty-nine patients (79%) completed the experiment.
Phenelzine sulfate, 60 mg daily, was significantly more effective than placebo in relieving symptoms of both depression and anxiety. Phenelzine sulfate, 30 mg daily, did not differ from the placebo. Only phenelzine sulfate, 60 mg daily, resulted in a median inhibition of platelet monoamine oxidase that exceeded 80%.
The results confirm a previous study that found phenelzine to be effective in the treatment of outpatients with depressive-anxiety states. Drug dosage is an important variable influencing clinical outcome in this patient group.
Author Affiliations
From the departments of psychiatry (Drs Ravaris, Nies, and Ives) and pharmacology and medicine (Dr Robinson and Ms Korson) and the Biometry Facility (Dr Lamborn), University of Vermont College of Medicine, Burlington. Dr Nies is now with the Department of Psychiatry, Dartmouth Medical School, Hanover, NH, and Dr Lamborn is now with the Biometry Division, Upjohn Research Laboratories, Kalamazoo, Mich. Dr Robinson is a Burroughs Wellcome Fund Scholar in Clinical Pharmacology.
Footnotes
Accepted for publication Feb 21, 1975.
Reprint requests to Department of Psychiatry, University of Vermont College of Medicine, Burlington, VT 05401 (Dr Ravaris).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Placebos, Drug Effects, and Study Design: A Clinician's Guide
Quitkin
Am. J. Psychiatry 1999;156:829-836.
ABSTRACT
| FULL TEXT
A Controlled Study of the Antidepressant Efficacy and Side Effects of ( -- )-Deprenyl: A Selective Monoamine Oxidase Inhibitor
Mann et al.
Arch Gen Psychiatry 1989;46:45-50.
ABSTRACT
An Efficacy Study of Isocarboxazid and Placebo in Depression, and Its Relationship to Depressive Nosology
Davidson et al.
Arch Gen Psychiatry 1988;45:120-127.
ABSTRACT
Antidepressant Specificity in Atypical Depression
Liebowitz et al.
Arch Gen Psychiatry 1988;45:129-137.
ABSTRACT
Phenelzine v Imipramine in Atypical Depression: A Preliminary Report
Liebowitz et al.
Arch Gen Psychiatry 1984;41:669-677.
ABSTRACT
Atypical Depression
Davidson et al.
Arch Gen Psychiatry 1982;39:527-534.
ABSTRACT
Monoamine Oxidase Inhibitors: A Review of Antidepressant Effectiveness
Quitkin et al.
Arch Gen Psychiatry 1979;36:749-760.
ABSTRACT
Use of Antidepressant Drugs in Schizophrenia
Siris et al.
Arch Gen Psychiatry 1978;35:1368-1377.
ABSTRACT
The Use of Antidepressants in Clinical Practice
Klerman and Hirschfeld
JAMA 1978;240:1403-1406.
ABSTRACT
|
